Dr. John DiPersio, Chief of the Division of Oncology at Washington University School of Medicine in St. Louis and the Virginia E. and Samuel J. Golman Professor of Medicine, joined RiverVest’s Scientific Advisory Board in 2014.
Dr. DiPersio’s clinical research focuses on fundamental and translational aspects of leukemia and stem cell biology. These studies include identification of genetic abnormalities in human leukemias, understanding processes involving stem cell and leukemia cell trafficking, and clinical and translational programs in both leukemia/myelodysplastic syndrome and stem cell transplantation.
Among his many accomplishments, Dr. DiPersio was instrumental in developing a drug called plerixafor that was approved by the U.S. Food and Drug Administration in 2008 to help treat multiple myeloma and non-Hodgkin’s lymphoma.
Dr. DiPersio is Chair of ASH Scientific Committee on Hematopoiesis, a member of the Board of Scientific Counselors (Clinical Science and Epidemiology) for the National Cancer Institute, and the 2013 recipient of the Daniel P. Schuster Distinguished Translational Investigator Award from Washington University. He has authored or co-authored more than 230 publications.
Dr. DiPersio received his M.D. and Ph.D. from the University of Rochester and his B.A. in Biology (Magna Cum Laude) from Williams College.